Silver Book Fact

Use of a monocolonal antibody with adjuvant chemotherapy in HER2+ individuals with operable cancer was associated with a 33 percent reduction in risk of death.

Romond, E, E Perez, J Bryant, V Suman, C Geyer, N Davidson, et al. Tastuzumab plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer. NEJM. 2005; 353: 1673-84. http://www.nejm.org/doi/full/10.1056/NEJMoa052122

Reference

Title
Tastuzumab plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer
Publication
NEJM
Publication Date
2005
Authors
Romond, E, E Perez, J Bryant, V Suman, C Geyer, N Davidson, et al.
Pages
1673-84
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • When detected early, the 5-year survival rate for colorectal cancer is 90%; however, only 39% of colorectal cancers are diagnosed early, mainly because of low rates of screening.  
  • An experimental drug has been found to extend the lives of kidney patients by about 3.5 months–from 7 to just under 11. It has also been shown to delay…  
  • According to the Pharmaceutical Research and Manufacturers of America, one of the most promising medicines in development is for glioblastoma. The medicine singles out and latches onto the receptors on…  
  • According to the Pharmaceutical Research and Manufacturers of America, a medicine in development targets late-stage metastatic melanoma. The medicine contains a gene encoding antigen that may be able to…  
  • There are nearly 14.5 million people in the U.S. living with a history of cancer.